Jennifer Carlisle is an Oncology physician affiliated with Emory University. OpenAlex indexes 98 publications with 2,138 citations (h-index 18); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1365 Clifton Rd NE
Atlanta, GA 303222208
Telephone
404-778-1900Registry record last updated 17 Mar 2018.
Clinical trials
- Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
Sponsor: Emory University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20254 payments$10,434openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year20251 payment
- Eli Lilly and CompanyProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
29.3%Phenothiazine10.9%Prochlorperazine Maleate100%Part D≥67 patientsOpioid Agonist8.5%Oxycodone Hcl81%Tramadol Hcl19%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
21.1%Serotonin-3 Receptor Antagonist11.8%Ondansetron Hcl82%Ondansetron Odt18%Part D<11 patientsOpioid Antagonist2.7%Naloxone Hcl100%Part D≥24 patients+ 4 more classes in this area
Sensory organs
18.6%Corticosteroid18.6%Dexamethasone100%Part D≥69 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Bispecific Antibodies in Non–Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration
American Society of Clinical Oncology Educational Book
2025 - Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision-Directed Delta-Like Ligand-3 Therapies
American Society of Clinical Oncology Educational Book
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Guyton, MD
Emory University
Keith Delman, MD
Emory University
Paolo Raggi, MD
Emory University
Monica Farley, MD
Emory University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”